Yahoo

AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial

Results from the PURSUIT Phase IIb trial for AstraZeneca’s (AZN) AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
The American Journal of Managed Care

Rates of Elevated LDL-C Have Decreased, but Awareness, Treatment Still Suboptimal

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...
clinicaladvisor.com

Lerodalcibep Reduces LDL-C in Patients With CVD or at Risk for CVD

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...
Science Daily

Most younger adults with high LDL-C levels do not take a statin

Despite recommendations, less than 45 percent of adults younger than 40 years with an elevated low-density lipoprotein cholesterol (LDL-C) level of 190 mg/dL or greater receive a prescription for a ...
Medical Xpress

Study finds U-shaped association between LDL-C and mortality risk in acute ischemic stroke patients

The general perception supports the mantra of "lower is better" for low-density lipoprotein cholesterol (LDL-C) levels in cardiovascular disease. However, during the acute stage of ischemic stroke, it ...
health.economictimes.indiatimes

“LDL-C: The Silent Killer in Your Bloodstream”

Cholesterol is a fatty substance found in the blood and is essential for building healthy cells. However, not all cholesterol is created equal. LDL-C is considered harmful because it transports ...
Monthly Prescribing Reference

Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C

A greater reduction LDL-C was seen for combo therapy; reductions also seen in all-cause mortality, major adverse CV events, stroke incidence. HealthDay News — Combination lipid-lowering therapy (LLT) ...
Medscape

LDL-C or apoB as the Best Target for Reducing Coronary Heart Disease

Atherogenic lipoprotein particles can vary considerably in their cholesterol content, but each particle contains only one molecule of apoB-100 (or simply apoB). As a result, serum concentration of ...
The American Journal of Managed Care

A Real-World Study of Patients With ASCVD Demonstrates Prevalence of High LDL-C, Demographic Disparities, and Underutilization of Lipid-Lowering Therapy

The results of a recent retrospective analysis of patients with established atherosclerotic cardiovascular disease (ASCVD) demonstrated that prior testing for lipoprotein(a) (Lp[a]) was associated ...
health.economictimes.indiatimes

“LDL-C Targets Are Changing: What You Thought Was Safe May Not Be”

Low-Density Lipoprotein Cholesterol (LDL-C), often labeled as “bad cholesterol,” is increasingly being recognized not just as a marker, but as the primary causal factor in the development of ...

American Journal of Preventive Cardiology Publishes Landmark Study on Sex Differences in Homozygous Familial Hypercholesterolemia in First Issue Under New Editor-in-Chief

The American Journal of Preventive Cardiology (AJPC) is proud to announce the publication of a landmark multinational study examining sex-based differences in homozygous familial hypercholesterolemia ...